Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio

Contributed by: ACCESS Newswire

Logo

ACCESSWIRE logo

Images

ACCESSWIRE associated0
ACCESSWIRE associated1

Tags

Dr. Falk Pharma GmbH
Healthcare & Pharmaceutical
Mergers and Acquisitions

More Like This

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

PR Newswire associated0

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer

PR Newswire associated0

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Kymanox® to Consolidate Brands of Acquired Companies

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

Business Wire logo

Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

XNK Therapeutics receives funding from Sweden's innovation agency Vinnova